Abstract
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.
Current Pharmacogenomics and Personalized Medicine
Title:Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Volume: 15 Issue: 2
Author(s): Jesus Rodriguez-Pascual*Antonio Cubillo
Affiliation:
- Centro Integral Oncologico Clara Campal (CIOCC), Madrid,Spain
Keywords: Colorectal cancer, bevacizumab, biomarkers, angiogenesis, chemotherapy, metastatic disease.
Abstract: Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several studies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal antibody.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Export Options
About this article
Cite this article as:
Rodriguez-Pascual Jesus *, Cubillo Antonio , Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review, Current Pharmacogenomics and Personalized Medicine 2017; 15 (2) . https://dx.doi.org/10.2174/1875692115666170815161754
DOI https://dx.doi.org/10.2174/1875692115666170815161754 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Liver-Directed Regional Therapy in the Multi-Disciplinary Management of Hepatocellular Cancer
Current Cancer Therapy Reviews The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Perspectives Offered by Single-Domain Antibodies in Clinical Diagnostic of Pediatric Tumors
Current Medicinal Chemistry Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies
Anti-Cancer Agents in Medicinal Chemistry Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Theranostic Aspects: Treatment of Cancer by Nanotechnology
Mini-Reviews in Medicinal Chemistry